Literature reviews

To download literature reviews on Neutropenia, click on the following articles:


New Synopses

Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer [149 KB]
Han Y, et al. Breast Cancer Res Treat 2012; 131(2):483-90
Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study [154 KB]
Phippen NT, et al. Gynecol Oncol. 2011; 123(2):360-4

2011

The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice [155 KB]
Johnsen HE, et al. Leukemia & Lymphoma 2011; [doi:10.3109/10428194.2011.643407] [Epub ahead of print]
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis [151 KB]
Cooper KL, Madan J, et al. BMC Cancer 2011; [doi:10.1186/1471-2407-11-404] [Epub ahead of print]
Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network [154 KB]
Hui EP, Leung LKS, et al. Support Care Cancer 2011; 19:1625-35
Effect of Primary Prophylactic Granulocyte Colony-Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-Stage Breast Cancer Patients Receiving Chemotherapy [158 KB]
Rajan SS, Lyman GH, et al. Medical Care 2011; 49(7):649-57
Predicting Individual Risk of Neutropenic Complications in Patients Receiving Cancer Chemotherapy [152 KB]
Lyman GH, Kuderer NM, et al. Cancer 2011; 117(9):1917-27
Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study [151 KB]
Tan H, Tomic K, et al. Curr Med Res Opin 2011; 27(1):79-86
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings [155 KB]
Okera M, Chan S, et al. Br J Cancer 2011; 104(3):407-12

2010

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma [158 KB]
Gerlier L, Lamotte M, Bosly A, et al. BMC Cancer 2010; 10:642
Risk assessment model for first cycle chemotherapy-induced neutropenia in patients with solid tumors [150 KB]
Lopez-Pousa A, Rifa J, et al. Eur J Cancer Care 2010; 19(5):648-55
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. [51 KB]
Aapro M, et al. Crit Rev Oncol Hematol. 2010;74:203-10
Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with Non-Hodgkin’s lymphoma treated with chemotherapy. [41 KB]
Gruschkus SK, et al. J Amer Geriatr Soc. 2010;58:1885-95

Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. [42 KB]
Rajan SS, et al. Breast Cancer Res Treat. 2010; e-pub ahead of print; doi 10.1007/s10549-010-1216-1
Comparing two risk models for chemotherapy-induced neutropenia. [47 KB]
Lopez-Pousa A, et al. Eur J Cancer Care. 2010;19:648-55 and Schwenkglenks M, et al. Support Care Cancer. 2010; e-pub ahead of print; doi 10.1007/s00520-010-0840-y

Acute myeloid leukaemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. [42 KB]
Lyman GH, et al. J Clin Oncol. 2010;28:2914-24

Risk of mortality in patients with cancer who experience febrile neutropenia. [35 KB]
Lyman GH, et al. Cancer. 2010; e-pub ahead of print; doi 10.1002/cncr.25332

Predicting the duration of chemotherapy-induced neutropenia: new scores and validation. [41 KB]
San Matias S, et al. Ann Oncol. 2010; e-pub ahead of print; doi 10.1093/annonc/mdq332

2009

Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer [153 KB]
Stokes ME, Muehlenbein CE, et al. J Manag Care Pharm 2009; 15(8):669-82
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. [42 KB]
Chirivella I, et al. Breast Cancer Res Treat. 2009;114(3):479-84

Impact of chemotherapy dose intensity on cancer patient outcomes. [42 KB]
Lyman GH, J Nat Compr Canc Netw. 2009;7:99-108

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. [31 KB]
Sharma R, et al. BMC Cancer. 2009;9:153

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. [39 KB]
Shayne M, et al. Cancer. 2009;15:5319-28

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis. [66 KB]
von Minckwitz G, et al. Eur J Cancer 2009;45(4):608-17

Risk of hospitalisation for neutropenic complications of chemotherapy in patients with primary solid tumours receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. [34 KB]
Weycker D, et al. Clin Ther. 2009;31(5):1069-81

2008

Docetaxel-related side effects and their management. [20 KB]
Baker J, et al. Eur J Oncol Nurs. 2008;12(3):253-68

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. [26 KB]
Bohlius J, et al. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD003189. DOI: 10.1002/14651858.CD003189.pub4

Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. [85 KB]
Dranitsaris G, et al. Am J Clin Oncol 2008;31(4):369-74

The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. [41 KB]
Zielinski CC, et al. Eur J Cancer. 2008;44(3):353-65

Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. [20 KB]
Ziepert M, et al. Ann Oncol. 2008;19(4):752-62

2007

Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. [42 KB]
Balducci L, et al. Oncologist. 2007;12(12):1416-24

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. [19 KB]
Kuderer NM, et al. J Clin Oncol. 2007;25(21):3158-67

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. [21 KB]
Pinto L, et al. Curr Med Res Opin. 2007;23(9):2283-95

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. [42 KB]
Shayne M, et al. Cancer. 2007;110(7):1611-20

2006

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. [38 KB]
Kuderer NM, et al. Cancer. 2006;106:2258-66

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. [50 KB]
Roché H, et al. J Clin Oncol. 2006;24(36):5664-71

2005

Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin’s lymphoma. [79 KB]
Blayney DW, et al. Oncologist 2005;10:138-49

Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. [20 KB]
Fortner BV, et al. Support Care Cancer. 2005;13:522-8

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. [28 KB]
Vogel CL, et al. J Clin Oncol. 2005;23:1178-84

Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices. [19 KB]
White N, et al. Cancer Nursing. 2005;28:62-9

2004

The CXCL12-CXCR4 chemotactic pathways as a target of adjuvant breast cancer therapies. [20 KB]
Epstein RJ. Nature reviews Cancer. 2004;4:1-9

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. [41 KB]
Lyman GH, et al. J Clin Oncol. 2004;22:4302-11

To top

Last update: 2012-01-27

The content of this website is intended for healthcare professionals.
All content is approved by the INC-EU study group members.

The INC-EU and this website are supported by an educational grant from

Amgen (Europe) GmbH.